Journal
SCIENCE
Volume 343, Issue 6178, Pages 1466-1470Publisher
AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/science.1251827
Keywords
-
Categories
Funding
- NCI NIH HHS [P30 CA016520, 3P30CA008748-47, R01 CA128978, P30 CA008748, CA128978, U01CA164947, R01 CA135509, CA016520, P50 CA116201, R01 CA116167, CA116167, U01 CA116167, U01 CA164947, CA135509, CA116201] Funding Source: Medline
Ask authors/readers for more resources
The cloning of the breast cancer susceptibility genes BRCA1 and BRCA2 nearly two decades ago helped set in motion an avalanche of research exploring how genomic information can be optimally applied to identify and clinically care for individuals with a high risk of developing cancer. Genetic testing for mutations in BRCA1, BRCA2, and other breast cancer susceptibility genes has since proved to be a valuable tool for determining eligibility for enhanced screening and prevention strategies, as well as for identifying patients most likely to benefit from a targeted therapy. Here, we discuss the landscape of inherited mutations and sequence variants in BRCA1 and BRCA2, the complexities of determining disease risk when the pathogenicity of sequence variants is uncertain, and current strategies for clinical management of women who carry BRCA1/2 mutations.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available